SPRY vs. ADMA, PTCT, RNA, ACLX, OGN, ZLAB, SWTX, RARE, AKRO, and ALVO
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs.
ARS Pharmaceuticals (NASDAQ:SPRY) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
In the previous week, ARS Pharmaceuticals had 11 more articles in the media than ADMA Biologics. MarketBeat recorded 28 mentions for ARS Pharmaceuticals and 17 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.34 beat ARS Pharmaceuticals' score of 0.30 indicating that ADMA Biologics is being referred to more favorably in the news media.
ARS Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
ADMA Biologics has higher revenue and earnings than ARS Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a net margin of 17.80% compared to ARS Pharmaceuticals' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat ARS Pharmaceuticals' return on equity.
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 40.1% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ADMA Biologics received 389 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 86.21% of users gave ARS Pharmaceuticals an outperform vote while only 72.13% of users gave ADMA Biologics an outperform vote.
ARS Pharmaceuticals presently has a consensus target price of $31.00, indicating a potential upside of 145.45%. ADMA Biologics has a consensus target price of $22.50, indicating a potential upside of 10.95%. Given ARS Pharmaceuticals' higher probable upside, equities research analysts clearly believe ARS Pharmaceuticals is more favorable than ADMA Biologics.
Summary
ADMA Biologics beats ARS Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 3/28/2025 by MarketBeat.com Staff
